Navigation Links
UCI researchers create new strategy for highly selective chemotherapy delivery
Date:9/25/2009

Irvine, Calif. UC Irvine researchers have created a new approach that vastly improves the targeting of chemotherapeutic drugs to specific cells and organs.

Kenneth Longmuir, associate professor of physiology & biophysics, and Richard Robertson, professor of anatomy & neurobiology, used liposomes, small spheres (less-than 100 nanometer in diameter) of naturally-occurring lipid molecules, as "packages" for the cancer chemotherapeutic agent doxorubicin, and a small peptide molecule to "address" the package to the targeted tissue.

Using this technology, the research team demonstrated that the doxorubicin was directed almost entirely to the targeted site with virtually no uptake by other organs, including lung, kidney and heart.

Their study appears online in the International Journal of Pharmaceutics.

Their approach is based on the fact that all tissues and organs, including all tumors, are surrounded by a dense region of sugar-containing molecules called polysaccharides. Most importantly, the particular chemical composition of the polysaccharides is different in each tissue and organ of the body. The chemical compositions of the polysaccharides of tumor regions are also different from normal tissue.

The research team developed a nanocarrier system that can recognize specific types of polysaccharide, and has demonstrated effective, organ-specific delivery of nanocarriers, and their therapeutic contents, based upon this polysaccharide-targeting approach.

In their study, the researchers used a peptide derived from a protein found in the microorganism Plasmodium, which is an organism well-known for its exceptional ability to exclusively target the polysaccharides of liver following entry into the bloodstream.

The drug doxorubicin is a chemotherapeutic agent commonly used as treatment for a variety of cancers. Although it is an effective anti-cancer agent, the usefulness of doxorubicin is compro
'/>"/>

Contact: Tom Vasich
tmvasich@uci.edu
949-824-6455
University of California - Irvine
Source:Eurekalert

Page: 1 2

Related medicine news :

1. UCI researchers create new strategy for highly-selective chemotherapy delivery
2. Pancreatic cancer: Researchers find drug that reverses resistance to chemotherapy
3. VA Honors Eye Researchers With Olin Teague Award
4. Researchers find drug-eluting stents safe, effective for PCI in diabetics
5. Researchers Propose Improved Cervical Cancer Screening
6. Researchers Perfect the View of Heart Disease
7. Mayo Clinic researchers lead national trial testing new treatment for chronic, severe indigestion
8. Indiana U medical researchers boost research and jobs with stimulus legislation grants
9. Canadian researchers discover the first-ever link between intelligence and curiosity
10. MUSC Researchers Concerned About Online Drug Availability
11. UCLA researchers develop biomarker for rapid relief of major depression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... PA (PRWEB) October 02, 2014 ... of the 2014 BIG Awards for Business program. ... and organizations with a proprietary judging process scored ... around the globe. , “The winners this year ... Russ Fordyce, Managing Director of the Business Intelligence ...
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, ... a neurotic personality style and prolonged stress may have ... suggests. Tracking 800 women over nearly four decades, ... jealous and moody -- which they defined as neurotic ... of developing Alzheimer,s compared to women scoring lowest in ...
(Date:10/2/2014)... By Steven Reinberg ... -- Living close to a major highway may raise your ... Among more than 5,000 postmenopausal women, those who lived within ... greater risk of developing high blood pressure than women living ... "The results of this study highlight the importance of our ...
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, Oct. 1, 2014 (HealthDay ... have a total of 500 confirmed cases of Enterovirus D68, ... since the summer, U.S. health officials reported Wednesday. Four ... but it,s not clear what role -- if any -- ... officials are also trying to determine if the virus is ...
(Date:10/1/2014)... team of scientists has shown that more than 80 ... existing drugs. , The study found that medicines called ... a genetic mutation that is present in more than ... are currently used, or are in clinical trials, for ... disorders. , Bowel cancer is the second-most common cancer ...
Breaking Medicine News(10 mins):Health News:Innovation Dominant Theme among 2014 Big Awards for Business Winners and Finalists 2Health News:Jealous, Moody Women May Face Higher Alzheimer's Risk, Study Says 2Health News:Jealous, Moody Women May Face Higher Alzheimer's Risk, Study Says 3Health News:Living Near a Highway May Be Bad for Your Blood Pressure 2Health News:Living Near a Highway May Be Bad for Your Blood Pressure 3Health News:42 States Reporting Respiratory Virus That Targets Kids 2Health News:42 States Reporting Respiratory Virus That Targets Kids 3Health News:Eighty percent of bowel cancers halted with existing medicines 2
... movement, study finds, , , WEDNESDAY, Feb. 18 (HealthDay News) ... of their impaired physical abilities, even if it,s been ... paralysis on the right side after a stroke were ... hold and move objects after they participated in robot-assisted ...
... finds misdiagnosis risk goes up as age goes down , , ... of numbness at a Detroit emergency room was discharged after ... woman with sharp pain in her left eye and loss ... doctors that she had a migraine. , And a 29-year-old ...
... health complications , during National Eating Disorders Awareness WeekLISLE, ... wants to call attention to the dangers surrounding ... treatment during National Eating Disorders Awareness Week -- Feb. ... concern and can cause a variety of oral health ...
... this week,s Journal of the American Medical,Association ... of Bioinformatics at the National Institute of Statistical Sciences, ... statistical limitations of a study,claiming that bisphenol A is ... liver,enzyme levels. The earlier study, published in JAMA ...
... 18 Specialty Underwriters,Alliance, Inc. (Nasdaq: SUAI ... on Friday, March 6, 2009 at 11:00 a.m. Eastern ... year end results for 2008. Detailed,financial information will ... 2009. , Interested parties may ...
... Feb. 18 Monthly menstrual cycles ... can include cramps, headaches and bloating. With more ... dysmenorrhea, regular vomiting also is a symptom. This ... to a study in the November/December 2008 issue ...
Cached Medicine News:Health News:Working With Robots May Help After a Stroke 2Health News:ER Less Likely to Diagnose Stroke in Younger Folks 2Health News:ER Less Likely to Diagnose Stroke in Younger Folks 3Health News:Dentists Often First to Spot Eating Disorders in Patients 2Health News:Dentists Often First to Spot Eating Disorders in Patients 3Health News:Specialty Underwriters' Alliance, Inc. Announces Fourth Quarter and Year End 2008 Conference Call 2Health News:Women Only: Cramps, Bloating and Now, Tooth Erosion? 2Health News:Women Only: Cramps, Bloating and Now, Tooth Erosion? 3
(Date:10/2/2014)... Echo Therapeutics, Inc. (NASDAQ: ECTE ... recent unauthorized public statements relating to Echo that have ... Shepard M. Goldberg, two members of the Echo Board ... the Echo Board by an affiliate of Platinum Management ... in numerous unauthorized public communications targeted at Echo stockholders, ...
(Date:10/2/2014)... 2014  Eli Lilly and Company (NYSE: LLY)  ... -- being studied for the treatment of systemic ... due to insufficient efficacy in two pivotal Phase ... safety concerns. ­­­­ In the ILLUMINATE ... endpoint, at either dose studied, of statistically significant ...
(Date:10/2/2014)... plc (NYSE: PRGO ; TASE), a public limited ... (the " Company "), today announced the expiration of ... of its new 1.30% Senior Notes due 2016 (the " ... Notes due 2018 (the " 2018 Exchange Notes "), $800,000,000 ... 2023 Exchange Notes ") and $400,000,000 of its new 5.30% ...
Breaking Medicine Technology:Echo Therapeutics Comments On Unauthorized Public Statements By Michael M. Goldberg, M.D. And Shepard M. Goldberg 2Echo Therapeutics Comments On Unauthorized Public Statements By Michael M. Goldberg, M.D. And Shepard M. Goldberg 3Echo Therapeutics Comments On Unauthorized Public Statements By Michael M. Goldberg, M.D. And Shepard M. Goldberg 4Lilly to Discontinue Development of Tabalumab Based on Efficacy Results in Phase 3 Lupus Studies 2Lilly to Discontinue Development of Tabalumab Based on Efficacy Results in Phase 3 Lupus Studies 3Perrigo Company plc Announces Expiration Of Exchange Offer For Its 1.30% Senior Notes Due 2016, 2.30% Senior Notes Due 2018, 4.00% Senior Notes Due 2023, 5.30% Senior Notes Due 2043 2Perrigo Company plc Announces Expiration Of Exchange Offer For Its 1.30% Senior Notes Due 2016, 2.30% Senior Notes Due 2018, 4.00% Senior Notes Due 2023, 5.30% Senior Notes Due 2043 3Perrigo Company plc Announces Expiration Of Exchange Offer For Its 1.30% Senior Notes Due 2016, 2.30% Senior Notes Due 2018, 4.00% Senior Notes Due 2023, 5.30% Senior Notes Due 2043 4
... 5, 2007 - Australian,biotechnology company Avexa (ASX:AVX) announced ... which,represents the first 24 week segment of its ... open-label section of the,trial (weeks 24 to 48) ... day as part of their daily treatment regime.,The ...
... Primary endpoint achieved -- , LAINATE, Italy - ... today positive preliminary results from its,phase II/III study ... is a broad spectrum, semi-synthetic,antibiotic that is not ... of Cosmo's MMX(tm) technology, which delivers the active,ingredient ...
Cached Medicine Technology:Avexa's Apricitabine Clinical Trial Update 2Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III,Data with Rifamycin MMX in Infectious Diarrhea 2
Diamond Point Bone Probe with Ortho-Grip® silicone rubber palm style handles and,stainless steel impactor caps....
The AV Plus DX pacing lead is designed for use with the St. Jude Medical Affinity VDR pulse generator. This single-lead pacing system provides reliable pacing therapy with the added benefits of AV sy...
Steroid eluting pacemaker leads...
The Guidant Fineline II Sterox is a steroid-eluting pacing lead designed for permanent implantation for either atrial or ventricular applications....
Medicine Products: